Skip to main content

Emerging concepts in heart failure management and treatment: focus on tachycardia-induced cardiomyopathy

Publication ,  Journal Article
Cabanillas, MVB; Colque, R; Tibaldi, MÁ; Kaplinsky, E; Perrone, S; Barbagelata, A
Published in: Drugs in Context
January 1, 2023

Tachycardia-induced cardiomyopathy is an entity characterized by reversible dysfunction of the left ventricle, which can be induced by different types of arrhythmia such as atrial fibrillation, atrial flutter, incessant supraventricular tachycardia and ventricular arrhythmia (more frequent causes). Correct identification of the causative arrhythmia and normalization of the heart rate (e.g through medical treatment, electrical cardioversion, ablation) can lead to recovery of left ventricular function. Tachycardia-induced cardiomyopathy should be suspected in patients with tachycardia and left ventricular dysfunction (heart failure setting), especially when there is no history of previous heart disease. Its usual phenotype is that of non-ischaemic/non-valvular dilated cardiomyopathy and it can occur in both children (main cause: permanent junctional reciprocating tachycardia) and adults (main cause: atrial fibrillation). With proper treatment, most cases recover within a few months, though there is a risk of relapse, especially when the causal arrhythmia reappears or its control is lost. This is a narrative review that comprehensively addresses the pathophysiology, clinical manifestations, and therapeutic management of tachycardia-induced cardiomyopathy.

Duke Scholars

Published In

Drugs in Context

DOI

EISSN

1740-4398

ISSN

1745-1981

Publication Date

January 1, 2023

Volume

2023

Related Subject Headings

  • 3214 Pharmacology and pharmaceutical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cabanillas, M. V. B., Colque, R., Tibaldi, M. Á., Kaplinsky, E., Perrone, S., & Barbagelata, A. (2023). Emerging concepts in heart failure management and treatment: focus on tachycardia-induced cardiomyopathy. Drugs in Context, 2023. https://doi.org/10.7573/dic.2022-8-4
Cabanillas, M. V. B., R. Colque, M. Á. Tibaldi, E. Kaplinsky, S. Perrone, and A. Barbagelata. “Emerging concepts in heart failure management and treatment: focus on tachycardia-induced cardiomyopathy.” Drugs in Context 2023 (January 1, 2023). https://doi.org/10.7573/dic.2022-8-4.
Cabanillas MVB, Colque R, Tibaldi MÁ, Kaplinsky E, Perrone S, Barbagelata A. Emerging concepts in heart failure management and treatment: focus on tachycardia-induced cardiomyopathy. Drugs in Context. 2023 Jan 1;2023.
Cabanillas, M. V. B., et al. “Emerging concepts in heart failure management and treatment: focus on tachycardia-induced cardiomyopathy.” Drugs in Context, vol. 2023, Jan. 2023. Scopus, doi:10.7573/dic.2022-8-4.
Cabanillas MVB, Colque R, Tibaldi MÁ, Kaplinsky E, Perrone S, Barbagelata A. Emerging concepts in heart failure management and treatment: focus on tachycardia-induced cardiomyopathy. Drugs in Context. 2023 Jan 1;2023.

Published In

Drugs in Context

DOI

EISSN

1740-4398

ISSN

1745-1981

Publication Date

January 1, 2023

Volume

2023

Related Subject Headings

  • 3214 Pharmacology and pharmaceutical sciences